IP Library Granted Patent US 12,398,420
Granted Patent B2
US 12,398,420 · App. 18/146,589 · Granted Aug 26, 2025

Compositions to detect adenovirus nucleic acids

Inventors: Mehrdad R. Majlessi (Escondido, CA); Ankur Shah (San Diego, CA); Amber Hillius (San Diego, CA); Pamela Douglass (Kansas City, MO); Daniel Kolk (Ramona, CA)
Assignee: GEN-PROBE INCORPORATED
C12Q1/6844C12Q1/701C12Q2600/16
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,398,420
App. No.
18/146,589
Granted
Aug 26, 2025
Kind
B2
Abstract

The disclosure is related to compositions, for targeting Adenovirus nucleic acid. Compositions include amplification oligomers and/or detection probe oligomers.

Claims (79)

1. A composition for determining the presence or absence of an Adenovirus target nucleic acid in a sample, the composition comprising:

a first amplification oligomer comprising a target hybridizing sequence selected from the group consisting of SEQ ID NOs:71, 72, 73, and 74;

a second amplification oligomer comprising a target hybridizing sequence selected from the group consisting of SEQ ID NOs:61 and 62; and

at least one additional amplification oligomer comprising a target hybridizing sequence selected from the group consisting of SEQ ID NOs:61, 62, 71, 72, 73, and 74, wherein the at least one additional amplification oligomers is different from the first amplification oligomer and the second amplification oligomer.

2. The composition of claim 1 , wherein the at least one additional amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:71, 72, 73, and 74.

3. The composition of claim 1 , wherein the at least one additional amplification oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:61 and 62.

4. The composition of claim 1 , wherein at least one of the first amplification oligomer, second amplification oligomer, and at least one additional amplification oligomer comprises a nucleic acid sequence that contains at least one 5-Me-C, at least one non-Watson Crick base, at least one degenerate base, or a combination thereof.

5. The composition of claim 1 , further comprising at least one detection probe oligomer configured to hybridize to a region of an Adenovirus amplicon amplifiable by the first, second, and at least one additional amplification oligomers, wherein the at least one detection probe oligomer comprises at least one of

(i) a detectable label,

(ii) a substitution at the 2′ position of at least one ribose moiety,

(iii) a blocking moiety at or near the 3′ end of the detection probe oligomer, wherein the blocking moiety is configured to prevent enzyme-mediated extension of the detection probe in an amplification reaction, and

(iv) a non-target-hybridizing sequence that contributes to the three-dimensional conformation of the detection probe oligomer.

6. The composition of claim 5 , wherein the at least one detection probe oligomer comprises a target hybridizing sequence selected from the group consisting of SEQ ID NOs:4, 10, 18, 20, 22, 24, 30, 36, 37, 39, 40, 63, 64, and 139.

7. The composition of claim 5 , wherein the at least one detection probe oligomer comprises a target hybridizing sequence that is from 18 to 36 nucleobases in length wherein the 18 to 36 nucleobases are all selected from contiguous nucleobases within SEQ ID NO:138.

8. The composition of claim 7 , wherein the at least one detection probe oligomer comprises

a detection probe oligomer comprising a target hybridizing sequence of SEQ ID NO:63,

a detection probe oligomer comprising a target hybridizing sequence of SEQ ID NO:64, or

a combination thereof.

9. The composition of claim 5 , wherein the at least one detection probe oligomer comprises the detectable label.

10. The composition of claim 9 , wherein the detectable label is a fluorophore.

11. The composition of claim 9 , wherein the at least one detection probe oligomer is a dual labeled detection probe oligomer comprising a fluorescent label and a quencher moiety that can quench a fluorescent emission from the fluorescent label.

12. The composition of claim 5 , wherein

(a) the at least one additional amplification oligomer comprises

a first additional amplification oligomer comprising a target hybridizing sequence selected from the group consisting of SEQ ID NOs:71, 72, 73, and 74, and

a second additional amplification oligomer comprising a target hybridizing sequence selected from the group consisting of SEQ ID NOs:61 and 62; and

(b) the at least one detection probe oligomer comprises

a first detection probe oligomer comprising a target hybridizing sequence of SEQ ID NO:63, and

a second detection probe oligomer comprising a target hybridizing sequence of SEQ ID NO:64.

13. The composition of claim 1 , further comprising

at least one additional first amplification oligomer comprising a target hybridizing sequence selected from the group consisting of SEQ ID NOs:1, 5, 11, 12, 25, 26, 31, 32, 33, 34, 35, and 38; and

at least one additional second amplification oligomer comprising a target hybridizing sequence selected from the group consisting of SEQ ID NOs:2, 3, 6, 7, 8, 9, 13, 14, 15, 16, 27, 28, 42, 43, 44, 45, 46, 139, 140, 141, 142, 143, 144, 145, 146, 147, 148, and 149.

14. A dried composition comprising:

(A) an oligomer combination to amplify an Adenovirus amplicon, the oligomer combination comprising

(1) a first amplification oligomer comprising a target hybridizing sequence selected from the group consisting of SEQ ID NOs:71, 72, 73, and 74;

(2) a second amplification oligomer comprising a target hybridizing sequence selected from the group consisting of SEQ ID NOs:61 and 62; and

(3) at least one additional amplification oligomer comprising a target hybridizing sequence selected from the group consisting of SEQ ID NOs:61, 62, 71, 72, 73, and 74, wherein the at least one additional amplification oligomers is different from the first amplification oligomer and the second amplification oligomer;

(B) an inorganic salt;

(C) a polymerase enzyme having 5′ to 3′ exonuclease activity;

(D) a reverse transcriptase; and

(E) dNTPs.

15. The dried composition of claim 14 , further comprising at least one detection probe oligomer that hybridizes to a region of the Adenovirus amplicon, wherein the at least one detection probe oligomer comprises at least one of

(i) a detectable label,

(ii) a substitution at the 2 ′ position of at least one ribose moiety,

(iii) a blocking moiety at or near within 5 residues of the 3 ′ end of the detection probe oligomer, wherein the blocking moiety prevents enzyme-mediated extension of the detection probe in an amplification reaction, and

(iv) a non-target-hybridizing sequence that contributes to the three-dimensional conformation of the detection probe oligomer.

16. The dried composition of claim 15 , wherein the at least one detection probe oligomer comprises

a detection probe oligomer comprising a target hybridizing sequence of SEQ ID NO:63,

a detection probe oligomer comprising a target hybridizing sequence of SEQ ID NO:64, or

a combination thereof.

17. The dried composition of claim 15 , wherein

(a) the at least one additional amplification oligomer comprises

a first additional amplification oligomer comprising a target hybridizing sequence selected from the group consisting of SEQ ID NOs:71, 72, 73, and 74, and

a second additional amplification oligomer comprising a target hybridizing sequence selected from the group consisting of SEQ ID NOs:61 and 62; and

(b) the at least one detection probe oligomer comprises

a first detection probe oligomer comprising a target hybridizing sequence of SEQ ID NO:63, and

a second detection probe oligomer comprising a target hybridizing sequence of SEQ ID NO:64.

18. A formulation for amplification and detection of an Adenovirus target nucleic acid, the formulation comprising:

(A) an oligomer combination to amplify an Adenovirus amplicon, the oligomer combination comprising

(1) a first amplification oligomer comprising a target hybridizing sequence selected from the group consisting of SEQ ID NOs:71, 72, 73, and 74;

(2) a second amplification oligomer comprising a target hybridizing sequence selected from the group consisting of SEQ ID NOs:61 and 62; and

(3) at least one additional amplification oligomer comprising a target hybridizing sequence selected from the group consisting of SEQ ID NOs:61, 62, 71, 72, 73, and 74, wherein the at least one additional amplification oligomers is different from the first amplification oligomer and the second amplification oligomer;

(B) at least one detection probe oligomer that hybridizes to a region of the Adenovirus amplicon;

(C) a polymerase enzyme having 5′ to 3′ exonuclease activity;

(D) a reverse transcriptase;

(E) dNTPs;

(F) EDTA; and

(G) water.

19. The formulation of claim 18 , wherein the at least one detection probe oligomer comprises a detectable label.

20. The formulation of claim 18 , wherein the at least one detection probe oligomer comprises

a detection probe oligomer comprising a target hybridizing sequence of SEQ ID NO:63,

a detection probe oligomer comprising a target hybridizing sequence of SEQ ID NO:64, or

a combination thereof.

21. The formulation of claim 18 , wherein

(a) the at least one additional amplification oligomer comprises

a first additional amplification oligomer comprising a target hybridizing sequence selected from the group consisting of SEQ ID NOs:71, 72, 73, and 74, and

a second additional amplification oligomer comprising a target hybridizing sequence selected from the group consisting of SEQ ID NOs:61 and 62; and

(b) the at least one detection probe oligomer comprises

a first detection probe oligomer comprising a target hybridizing sequence of SEQ ID NO:63, and

a second detection probe oligomer comprising a target hybridizing sequence of SEQ ID NO:64.

Assignments (4)
RELEASE OF SECURITY INTEREST RECORDED AT REEL/FRAME 065286/0407 Recorded Apr 24, 2026
From: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
To: HOLOGIC, INC.; GEN-PROBE INCORPORATED; FAXITRON BIOPTICS, LLC; BIOTHERANOSTICS, INC.; GEN-PROBE PRODESSE, INC.
Reel/Frame 075457/0767 →
SECURITY INTEREST Recorded Apr 8, 2026
From: BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.; CYTYC CORPORATION; SUROS SURGICAL SYSTEMS, INC.; GYNESONICS, INC.; BOLDER SURGICAL, LLC; FAXITRON BIOPTICS, LLC; HEALTH BEACONS, INC.; HOLOGIC, INC.
To: ROYAL BANK OF CANADA, AS COLLATERAL AGENT
Reel/Frame 075462/0440 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 13, 2024
From: MAJLESSI, MEHRDAD R.; SHAH, ANKUR; HILLIUS, AMBER; DOUGLAS, PAMELA; KOLK, DANIEL P.
To: GEN-PROBE INCORPORATED
Reel/Frame 066755/0311 →
SECURITY INTEREST Recorded Oct 19, 2023
From: HOLOGIC, INC.; FAXITRON BIOPTICS, LLC; BIOTHERANOSTICS, INC.; GEN-PROBE INCORPORATED; GEN-PROBE PRODESSE, INC.
To: BANK OF AMERICA, N.A., AS COLLATERAL AGENT
Reel/Frame 065286/0407 →
Continuity (5)
Continuation 17820256 · Aug 17, 2022
Continuation 17834578 · Jun 7, 2022
Continuation 16497229
Provisional Application 62476753 · Mar 25, 2017
Related Publication 20230203572A1 · Jun 29, 2023
References Cited (36)
US 8715922B2 · De Jong et al. · 2014 [cited by applicant]
US 10106860B2 · Yoo et al. · 2018 [cited by applicant]
US 11384387B2 · Majlessi et al. · 2022 [cited by applicant]
US 20060240412A1 · Hall et al. · 2006 [cited by applicant]
US 20060286580A1 · Lin et al. · 2006 [cited by applicant]
US 20070092871A1 · Lodes et al. · 2007 [cited by applicant]
US 20070099177A1 · Helm · 2007 [cited by applicant]
US 20090105092A1 · Lipkin et al. · 2009 [cited by applicant]
US 20100086908A1 · Prudent · 2010 [cited by applicant]
US 20120089859A1 · Wang · 2012 [cited by applicant]
US 20130209992A1 · Becker et al. · 2013 [cited by applicant]
US 20200263242A1 · Majlessi et al. · 2020 [cited by applicant]
CN 105018488A · 2015 [cited by applicant]
CN 106222304A · 2016 [cited by applicant]
ES 2344443A1 · 2010 [cited by applicant]
KR 101749587B1 · 2017 [cited by applicant]
WO 2002067861A2 · 2002 [cited by applicant]
WO 2005100611A2 · 2005 [cited by applicant]
WO 2007130519A2 · 2007 [cited by applicant]
WO 2008016988A1 · 2008 [cited by applicant]
WO 2011079064A1 · 2011 [cited by applicant]
WO 2012046219A2 · 2012 [cited by applicant]
WO 2012089240A1 · 2012 [cited by applicant]
WO 2018183124A1 · 2018 [cited by applicant]
European Search Report mailed Jul. 23, 2024, issued in corresponding European Application No. 24168848.0, filed Mar. 23, 2018, 6 pages. [cited by applicant]
Khodakov et al., “DNA capture-probe based separation of double-stranded polymerase chain reaction amplification products in poly(dimthylsiloxane) microfluidic channels,” Biomicrofluidics 6:026503, 2012. [cited by applicant]
Xu et al., “Species-Specific Identification of Human Adenoviruses by a Multiplex PCR Assay,” J. Clin. Microbiol. 28:4114-4120, Nov. 2000. [cited by applicant]
U.S. Appl. No. 16/497,229, Final Office Action mailed Nov. 8, 2021. [cited by applicant]
U.S. Appl. No. 16/497,229, Non-Final Office Action mailed Apr. 8, 2021. [cited by applicant]
U.S. Appl. No. 16/497,229, Notice of Allowance mailed Mar. 8, 2022. [cited by applicant]
U.S. Appl. No. 16/497,229, Notice of Allowance mailed Apr. 4, 2022. [cited by applicant]
U.S. Appl. No. 16/497,229, Requirement for Restriction/Election mailed Oct. 9, 2020. [cited by applicant]
WIPO Application No. PCT/US2018/024141, International Preliminary Report on Patentability mailed Oct. 1, 2019. [cited by applicant]
WIPO Application No. PCT/US2018/024141, International Search Report and Written Opinion mailed Jul. 25, 2018. [cited by applicant]
Damen et al., “Real-Time PCR with an Internal Control for Detection of All Known Human Adenovirus Serotypes,” J. Clin. Microbiol. 46:3997-4003, 2008; Published Ahead of Print Oct. 15, 2008. [cited by applicant]
Wong et al., “Detection of a Broad Range of Human Adenoviruses in Respiratory Tract Samples Using a Sensitive Multiplex Real-Time PCR Assay,” J. Med. Virol. 80:856-865, 2008. [cited by applicant]